NASDAQ · RPTX
Repare Therapeutics Inc.
$2.65$0.00 (0.0%)
Repare Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
Loading market information…
NASDAQ · IMUX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Immunic, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.93. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Immunic, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$2.50-1,036.36% vs estimate |
| $0.00-100.0% vs estimate |
| Q3 2024 | Nov 7, 2024 | -$2.40-9.09% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.65$0.00 (0.0%)
Repare Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$0.43$0.00 (0.0%)
Vaxart, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.17% below the high.
$1.35$0.00 (0.0%)
Cibus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.79% below the high.
$1.76$0.00 (0.0%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 50.56% below the high.
$1.35$0.00 (0.0%)
PMV Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.32% below the high.
$0.62$0.00 (0.0%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
